Oxford Nanopore Technologies plc (London Stock Exchange: ONT) is a British life-sciences technology company developing nanopore-based systems for the direct electronic analysis of DNA and RNA. Founded in 2005 as a University of Oxford spin-out, the company has expanded from a portable sequencing concept into a global platform serving academic research, clinical development, pharmaceutical quality control, infectious-disease surveillance, industrial biology and population-scale genomics.
The company generated £223.9 million of revenue in 2025, representing growth of 22.2% on a reported basis and 24.2% at constant currencies. Its adjusted EBITDA loss narrowed by £31.2 million to £86.7 million, but the statutory loss remained substantial at £145.2 million. Cash, cash equivalents and other liquid investments declined to £302.8 million at December 31, 2025 from £403.8 million a year earlier.
Commercial momentum weakened during the first half of 2026. Preliminary revenue reached approximately £116.5 million, up 10% on a reported basis and 12% at constant currencies, but performance fell below management expectations because of export restrictions and commercial changes in China, disruption in the Middle East and the timing of customer orders in the Americas. Liquid resources declined further to approximately £234.5 million by June 30.
The Oxford Nanopore Technologies company profile is therefore defined by a tension between scientific adoption and financial execution. Its high-throughput PromethION platform is expanding, clinical and biopharmaceutical revenue are growing faster than the core research business, and regulated-market partnerships are broadening the company’s opportunity. Investors must nevertheless determine whether new chief executive Francis Van Parys can convert that growth into adjusted EBITDA breakeven during 2027 and positive cash flow during 2028.
What does Oxford Nanopore Technologies do, and how does nanopore sequencing analyse DNA and RNA?
Oxford Nanopore has developed a molecular-sensing platform that analyses DNA and RNA by passing individual molecules through extremely small protein pores embedded within an electrically resistant membrane. Changes in electrical current as each molecule moves through a pore are measured and translated into information about its sequence.
Unlike sequencing approaches that require a complete run before analysis begins, Oxford Nanopore systems stream information in real time. Researchers can begin examining results while sequencing continues, stop the run once sufficient information has been collected or extend it when additional depth is needed.
The technology can analyse short through ultra-long fragments of native DNA and RNA. Working directly with native molecules can preserve information about chemical modifications and RNA characteristics that may require additional processing or separate testing on other platforms.
Long reads can help researchers resolve structural changes, repeated regions and complex sections of a genome that are difficult to reconstruct from many short fragments. Real-time analysis can also be valuable in infectious-disease outbreaks, environmental monitoring and other situations where speed matters.
Oxford Nanopore designed the platform to operate at different scales. A small laboratory or field researcher can use a portable MinION device, while institutions running large human-genomics or population-sequencing programmes can use PromethION systems containing multiple independently operated flow cells.
This flexibility is one of the company’s principal commercial differentiators. Customers can begin with relatively accessible equipment and expand capacity as sample volumes, research programmes and funding increase.
How did Oxford Nanopore develop from a university spin-out into a listed genomics company?
Oxford Nanopore was established in 2005 as Oxford Nanolabs by Gordon Sanghera, Spike Willcocks and Professor Hagan Bayley, with early backing from IP Group. The business emerged from research into the use of nanopores for molecular analysis.
Sanghera became chief executive and led the company through private financing rounds, product development, commercial launch and its eventual listing on the London Stock Exchange in September 2021.
The company’s early strategy differed from the established sequencing market. Rather than beginning with a large centralised laboratory instrument, Oxford Nanopore developed MinION as a portable sequencer capable of connecting to a computer and generating information in real time.
MinION allowed researchers to move sequencing closer to the sample. Nanopore systems have since been used in laboratories, hospitals, farms, public-health facilities and field-research locations. The company said its technology was being used in more than 125 countries by July 2026.
Oxford Nanopore subsequently broadened the portfolio through GridION and PromethION. GridION combines multiple MinION-compatible flow cells with integrated computing, while PromethION provides substantially greater capacity for institutional genomics programmes.
The 2021 flotation supplied capital for manufacturing expansion, research and development, commercial hiring and instrument placement. The listed-company experience has nevertheless been challenging. Revenue and adoption have grown, but the shares remained well below their flotation price by August 2026 as investors questioned losses, cash requirements and the timetable for sustainable profitability.
How do MinION, GridION and PromethION address different sequencing markets and customer needs?
MinION is Oxford Nanopore’s best-known product and remains central to the company’s objective of making sequencing broadly accessible. The portable device uses replaceable flow cells containing nanopores and is designed for lower-throughput laboratory, education and field applications.
GridION is a benchtop system capable of running five MinION-compatible flow cells independently. It includes integrated computing and is intended for laboratories requiring greater throughput and a more standardised workflow without moving immediately to the largest PromethION systems.
PromethION is the company’s high-throughput product family. Different configurations allow customers to run multiple higher-capacity flow cells and support applications including human whole-genome sequencing, rare-disease studies, cancer research, population genomics and pharmaceutical development.
The financial importance of PromethION has increased rapidly. Revenue from the product range rose 43.1% to £110.6 million in 2025 from £77.3 million in 2024. MinION product-range revenue increased only 2.4% to £56.3 million, while kits, services and other products generated approximately £57 million.
PromethION accounted for almost half of group revenue in 2025. Its expanding installed base can create recurring demand for flow cells, preparation kits and related products as customers increase the number and scale of sequencing runs.
The company’s challenge is to balance accessibility with economic scale. MinION attracts new users and supports experimentation, while PromethION can generate larger consumables revenue from institutional customers. A healthy platform requires continued user creation alongside increasing utilisation by established customers.
How does Oxford Nanopore make money from instruments, flow cells, software and commercial partnerships?
Oxford Nanopore generates revenue from sequencing devices, consumable flow cells, sample-preparation kits, software, services and collaboration or licensing agreements.
Devices create the installed base, but recurring consumables are central to the long-term business model. Each sequencing run requires a flow cell, while laboratories also purchase preparation kits and associated materials. Increased utilisation can therefore generate additional revenue without the company needing to win a completely new customer for each transaction.
Oxford Nanopore sells some instruments directly, places others with customers under leasing or access arrangements and uses distributors in selected markets. This flexibility can accelerate adoption, although it may require the company to invest in equipment before recovering its cost through future consumable usage.
Large PromethION customers can generate substantial recurring demand. The economics improve when institutions increase utilisation of instruments already installed because customer-acquisition and placement costs do not need to be repeated for every additional flow cell.
The company is also trying to create more predictable revenue from regulated and repeatable workflows. Its Q-Line products use fixed hardware and software configurations intended for routine applications in clinical research, pharmaceutical quality control, veterinary testing, environmental monitoring and outbreak surveillance.
Collaboration and licensing arrangements provide another potential income stream. These may include technology access, development funding or commercial partnerships with diagnostics and life-sciences companies. The timing can be irregular, and management has acknowledged that some collaboration and licensing income expected during the second half of 2026 may be non-recurring.
Why is PromethION becoming the principal engine of Oxford Nanopore’s commercial growth?
PromethION moves Oxford Nanopore beyond portable and small-scale sequencing into the largest institutional genomics workloads.
The product family generated £110.6 million of revenue in 2025, up 43.1%, while MinION-related revenue increased only modestly. Preliminary PromethION revenue also rose approximately 15% during the first half of 2026.
High-throughput systems can support human whole-genome sequencing, population studies, cancer programmes, pharmaceutical research and large rare-disease projects. These applications consume more flow cells and preparation materials than individual small-scale experiments.
The installed-base model becomes more attractive when existing customers increase instrument utilisation. Higher usage raises recurring revenue without requiring Oxford Nanopore to repeat the entire sales and installation process.
PromethION also enables the company to compete more directly for workloads traditionally served by large centralised sequencing systems. Its differentiation rests on long reads, real-time analysis and the direct sequencing of native DNA and RNA.
Customers still compare cost per sample, accuracy, throughput, computing requirements, sample preparation and compatibility with established laboratory systems. PromethION’s revenue growth demonstrates commercial traction, but the platform must continue improving reliability, automation and workflow simplicity to gain market share.
How is Oxford Nanopore moving from academic research into regulated clinical applications?
Research remained Oxford Nanopore’s largest end market in 2025, contributing £148.6 million, or approximately 66% of group revenue. Clinical revenue, however, increased 59.9% to £29.8 million, while BioPharma revenue rose 30.4% to £18.1 million and Applied Industrial revenue increased 27.2% to £27.5 million.
The faster growth of applied markets is strategically important. Academic demand can fluctuate with government and university funding, while validated clinical and industrial workflows may produce more regular utilisation once adopted.
Oxford Nanopore reached a regulatory milestone in January 2026 when GridION Dx became CE and UKCA marked, making it the company’s first registered in vitro diagnostic device in the United Kingdom and Europe.
The registration confirms that the device meets applicable quality, safety and performance requirements. It does not mean that every assay performed on the platform is approved for diagnostic use.
Oxford Nanopore had not commercially launched GridION Dx or announced general product availability by August 2, 2026. Individual assays and clinical workflows may also require separate validation, registration, laboratory accreditation and reimbursement arrangements.
Commercialising clinical sequencing therefore requires more than securing registration for the instrument. The company must help customers establish validated tests, demonstrate medical utility and integrate sequencing into laboratory processes that are designed for routine patient care.
Why are the bioMérieux and Cepheid partnerships important to Oxford Nanopore’s clinical strategy?
Oxford Nanopore is working with established diagnostics companies to make sequencing easier to deploy in routine infectious-disease workflows.
The company and bioMérieux launched AmPORE-TB in November 2025. The research-use-only system combines Oxford Nanopore sequencing with automated analysis to identify mutations associated with drug-resistant tuberculosis. It is designed and manufactured by Oxford Nanopore and distributed by bioMérieux.
The workflow is intended to analyse genes associated with tuberculosis resistance and provide same-day information. World Health Organization guidance recommends targeted next-generation sequencing as a testing class for detecting resistance to tuberculosis medicines.
AmPORE-TB was identified as one of the targeted methods meeting specified class-based performance criteria for resistance-associated mutations. The commercial workflow nevertheless remains labelled for research use only and continues to follow a development path towards regulatory approval for clinical use.
Oxford Nanopore has also partnered with Cepheid to combine Cepheid’s GeneXpert sample-preparation system with nanopore sequencing. The companies demonstrated an initial proof of concept and expanded the collaboration into a second phase in April 2026.
The planned Cepheid workflow remained focused on research use rather than immediate regulated diagnosis. Its strategic importance lies in reducing sample-preparation complexity and linking nanopore sequencing with a widely used automated laboratory platform.
These partnerships could address one of the largest barriers to sequencing adoption. Many diagnostic laboratories need automated preparation, fixed operating procedures, validated software and clear interpretation rather than an open research platform requiring specialist bioinformatics knowledge.
bioMérieux and Cepheid also provide commercial channels and established customer relationships. Their involvement could help Oxford Nanopore reach clinical laboratories without independently developing every component of the workflow.
How could pharmaceutical quality control become a valuable recurring market for nanopore sequencing?
Oxford Nanopore is targeting pharmaceutical and biotechnology companies that need to verify the identity, integrity and quality of biological materials used in research and manufacturing.
Potential applications include the characterisation of plasmids, cell lines, viral vectors, messenger RNA products and other materials involved in advanced therapies and biomanufacturing. Direct analysis of DNA and RNA can provide information that might otherwise require several separate testing methods.
The company’s Q-Line products are intended for controlled and Good Manufacturing Practice-oriented environments. Fixed hardware and software configurations can help laboratories validate a process and continue using it without unexpected changes to the underlying system.
BioPharma revenue increased 30.4% during 2025 and approximately 25% during the first half of 2026. The growth indicates adoption beyond exploratory research, although the segment still represents a relatively small portion of group revenue.
Pharmaceutical quality control could become commercially attractive because manufacturing workflows repeat across many batches. A sequencing method integrated into routine release or process-control testing may generate recurring flow-cell and kit demand.
Adoption may take time. Pharmaceutical companies require extensive validation, documentation and regulatory confidence before replacing established quality-control methods. Oxford Nanopore must demonstrate reproducibility, workflow stability and economic value alongside scientific capability.
What do Oxford Nanopore’s 2025 financial results reveal about commercial progress and continuing losses?
Oxford Nanopore reported £223.9 million of revenue in 2025, compared with £183.2 million in 2024. Gross profit increased 24.6% to £131.3 million, while reported gross margin improved to 58.6%.
Adjusted gross margin, excluding a restructuring-related inventory charge, reached 59.4%. The company is attempting to increase margins through pricing changes, manufacturing automation, higher utilisation and greater recycling of electronic flow-cell components.
The adjusted EBITDA loss narrowed from £117.9 million to £86.7 million. The improvement reflected revenue growth, higher gross profit and cost controls, but the company remained far from statutory profitability.
The reported operating loss was £155.3 million and the loss for the year was £145.2 million. Restructuring costs reached £22.6 million, including headcount reductions, changes to research and development priorities and adjustments to the product portfolio.
Research and product development remain expensive. Oxford Nanopore capitalised £41.5 million of development expenditure during 2025, up from £34.7 million in 2024.
Capitalising qualifying development expenditure moves the cost onto the balance sheet before it is amortised in later periods. Investors therefore need to consider both adjusted earnings and the actual movement in cash and liquid resources.
Cash, cash equivalents and liquid investments declined by £101 million during 2025 to £302.8 million. The company remained better funded than many loss-making life-sciences businesses, but the decline explains why reaching breakeven before reserves fall too far remains central to the investment case.
Why did Oxford Nanopore’s first-half 2026 growth fall below management expectations?
Preliminary first-half revenue reached approximately £116.5 million, representing growth of 10% on a reported basis and 12% at constant currencies. Management said the result was below its expectations.
Revenue in China declined approximately 16% following enhanced export-control restrictions and changes to the company’s commercial operations. Middle East revenue fell approximately 14% amid geopolitical disruption.
China accounted for 9.6% of group revenue in 2025, making the weakness commercially significant without being dominant across the entire group.
Oxford Nanopore also faced the completion of the PRECISE II population-genomics contract in Singapore, which reduced the year-on-year comparison in the Asia-Pacific region.
Revenue in the Americas grew approximately 12% at constant currencies but was constrained by the timing of customer orders and contract awards. Management said it did not expect to recover all of the first-half timing effect before the end of 2026.
Performance outside China and the Middle East was stronger, with group revenue increasing approximately 16% at constant currencies. Europe, the Middle East, Africa and India collectively grew around 23% despite the disruption in parts of the region.
Applied Markets revenue increased approximately 22%, led by 35% Clinical growth and 25% BioPharma growth. Research revenue increased only 5%, reflecting the completion of several large programmes.
The results support the strategic shift toward applied markets but also reveal continuing regional and project volatility. Oxford Nanopore needs a broader base of routine customers to reduce sensitivity to individual programmes and procurement timing.
Is Oxford Nanopore still on track to reach adjusted EBITDA breakeven during 2027?
Oxford Nanopore retained its headline 2026 guidance for constant-currency revenue growth of approximately 21% to 25%. The guidance includes collaboration and licensing opportunities expected during the second half, some of which may be non-recurring.
Excluding those additional opportunities, management expects constant-currency growth of approximately 16% to 20%. The lower underlying range reflects China weakness, Middle East disruption and Americas orders that are not expected to be recovered fully by year-end.
The distinction matters because recurring product and consumables revenue provides stronger evidence of durable commercial progress than one-time licensing or collaboration payments.
Oxford Nanopore maintained its expectation of an approximately 62% gross margin in 2026. Higher component recycling, automation, pricing changes and product mix are expected to support the improvement from 2025.
Management also retained its objective of reaching adjusted EBITDA breakeven during 2027 and positive cash flow during 2028.
Achieving those targets requires continued revenue growth, improving gross margins and careful control of operating expenditure. Delays in clinical adoption, further regional weakness or greater investment under the new management strategy could move the timetable again.
The full interim results scheduled for August 19, 2026 should provide more information about first-half expenses, cash flows, margins and the strategic priorities of the new chief executive.
How strong is Oxford Nanopore’s balance sheet after the decline in liquid resources?
Oxford Nanopore held approximately £234.5 million of cash, cash equivalents and other liquid investments at June 30, 2026. That was £68.3 million below the December 2025 position and approximately £169 million below the amount held at the end of 2024.
The balance sheet still gives the company meaningful capacity to invest in product development, commercial expansion and regulatory programmes. Oxford Nanopore also had lease liabilities of £41.5 million at the end of 2025 but did not carry a conventional bank-debt burden comparable with many leveraged businesses.
The £68.3 million first-half decline in liquid resources should not be treated automatically as equivalent to operating cash burn because the full interim cash-flow statement had not yet been published. Working capital, development investment, capital expenditure and movements between cash and other liquid investments can all affect the balance.
The principal concern is the rate at which financial resources are declining before sustainable profitability. Cash requirements may exceed the adjusted EBITDA loss because of capitalised development expenditure, working capital and equipment placed with customers.
Management expects the cash profile to improve as the installed base generates more consumables revenue, gross margins rise and operating costs increase more slowly than revenue.
A material revenue miss or delay to the 2027 breakeven target could renew concern about a future capital raise. The current liquidity provides time, but it does not offer unlimited protection if substantial losses continue.
How has the Oxford Nanopore share price performed during 2026?
Oxford Nanopore shares closed at approximately 113.4 pence on July 31, 2026. The stock rose about 5.2% from its July 24 closing price of 107.8 pence but remained approximately 8.6% below the June 30 close of 124.1 pence.
The shares were also around 11.7% below the approximately 128.4-pence level recorded at the end of 2025.
The stock traded within an approximate 52-week range of 95.61 pence to 224.80 pence. The shares touched the 52-week low on July 13, the day Oxford Nanopore disclosed that first-half trading had fallen below management expectations.
With approximately 975.3 million shares in issue, the July 31 price implied an equity-market value of roughly £1.11 billion.
That valuation was equivalent to approximately 4.9 times 2025 revenue. The calculation is an illustrative equity-value-to-revenue comparison rather than an enterprise-value multiple and does not account for the company’s substantial liquid resources.
A price-to-earnings ratio is not meaningful because Oxford Nanopore remains loss-making. Investors are valuing the business on its sequencing technology, growth prospects, intellectual property, installed base and expected path to profitability.
Market sentiment remains divided. Oxford Nanopore is growing faster than many established life-sciences tools businesses, but the July update showed that maintaining growth above 20% may depend partly on licensing and collaboration transactions alongside a stronger second half.
Who owns and leads Oxford Nanopore following the transition from founder-led management?
Francis Van Parys became chief executive and joined the board on March 2, 2026. Gordon Sanghera stepped down as chief executive and director on the same date but remained employed as a senior adviser to support the transition through early 2027.
Van Parys previously led acute-care diagnostics company Radiometer and held senior roles at Cytiva and GE Healthcare. His experience is closely aligned with scaling regulated life-sciences platforms and commercial operations.
Duncan Tatton-Brown serves as chair, while Nick Keher is chief financial officer. The board also includes non-executive directors with experience across healthcare, technology, consumer businesses and international growth.
At December 31, 2025, EIT Oxford Holdings was the largest disclosed shareholder with 17.68%. IP Group held 7.86% directly and a further 1.22% through managed funds.
Tencent Holdings held 6.53%, bioMérieux held 6.11%, Novo Holdings held 5.45% and G42 held 4.59%. Other disclosed investors included Baillie Gifford, M&G Investments, Oracle and Vanguard.
The shareholder register combines strategic technology and diagnostics companies with institutional investors. bioMérieux is both a shareholder and commercial partner, while Oracle provides another connection to the broader technology sector.
The transition from Sanghera to Van Parys represents more than a change of leadership. Oxford Nanopore is moving from a founder-led product-development phase towards a period requiring greater commercial discipline, regulated-market execution and financial delivery.
How does Oxford Nanopore compete with Illumina, PacBio and other sequencing technologies?
Oxford Nanopore competes within a sequencing market that includes established short-read systems, other long-read technologies and specialised diagnostic platforms.
Short-read sequencing is deeply embedded in many research and clinical laboratories. It can offer high accuracy and mature workflows for applications where many small DNA fragments provide sufficient information.
Oxford Nanopore competes through real-time analysis, native DNA and RNA sequencing, portable devices, flexible throughput and the ability to generate long and ultra-long reads. These capabilities can be valuable when researchers need to examine structural variation, complete genomes, RNA isoforms or rapidly evolving pathogen samples.
PacBio provides another long-read sequencing approach and is particularly associated with highly accurate circular-consensus sequencing. Customers may select between technologies based on accuracy, read length, throughput, sample preparation, cost and existing laboratory infrastructure.
Oxford Nanopore’s broad device range may provide an accessibility advantage, while competitors benefit from established validation, customer familiarity and specialised performance in particular applications.
The company must continue improving accuracy, automation and ease of use. Scientific performance alone will not determine adoption in routine clinical and industrial markets, where customers also require predictable workflows, quality systems and regulatory support.
What are the biggest commercial, financial and regulatory risks facing Oxford Nanopore?
Profitability remains the most visible risk. Oxford Nanopore continues to generate substantial statutory and adjusted losses, while liquid resources have declined significantly. Failure to reach adjusted EBITDA breakeven during 2027 could increase concern about future financing.
Revenue quality is another issue. Full-year 2026 guidance includes collaboration and licensing income that may not recur. Investors need to distinguish durable flow-cell and kit consumption from one-time commercial payments.
Research funding can affect customer demand. The company has experienced pressure in parts of the United States research market, while several large research and population-genomics projects have reached completion.
China presents regulatory and geopolitical risk. Export-control restrictions and changes to commercial operations contributed to a 16% revenue decline during the first half of 2026.
Large projects can make growth uneven. The conclusion of population-genomics programmes or delays in customer procurement may produce difficult comparisons even when the broader user base continues expanding.
Clinical expansion requires regulatory execution. GridION Dx registration is an important milestone, but the device had not yet been commercially launched, and individual tests may require separate regulatory approval and reimbursement.
Competition may pressure pricing and market share. Oxford Nanopore must compete with established sequencing companies, existing laboratory methods and emerging technologies while continuing to invest heavily in innovation.
Intellectual-property disputes add uncertainty. Oxford Nanopore has disclosed legal proceedings against MGI and BGI-related entities involving alleged trade-secret infringement, breach of confidence and breach of contract. The outcome and financial effect remain uncertain.
Capitalised development costs also require careful interpretation. Investment in new products is necessary, but the accounting treatment can make adjusted operating performance appear stronger than immediate cash generation.
What is the growth outlook for Oxford Nanopore Technologies through 2027?
Oxford Nanopore enters its next phase with a larger revenue base, a stronger PromethION franchise and growing exposure to clinical and biopharmaceutical markets.
PromethION is likely to remain the main near-term growth engine. More instruments in use and higher customer utilisation should increase recurring demand for flow cells, preparation kits and related products.
Clinical expansion offers the largest strategic opportunity. GridION Dx provides a regulated-device foundation, while bioMérieux and Cepheid bring commercial channels and workflow expertise. These partnerships must progress from research-use applications towards validated routine testing before they can generate their full economic potential.
Biopharmaceutical quality control provides another route to recurring consumption. Pharmaceutical customers may adopt nanopore sequencing in plasmid, cell-line, viral-vector and messenger-RNA workflows if Oxford Nanopore can demonstrate reliability and regulatory compatibility.
Research will remain essential even if its percentage of group revenue declines. Academic users develop applications, generate publications and create scientific evidence that can later support clinical and industrial adoption.
The first-half 2026 miss has raised the execution threshold. Oxford Nanopore needs a stronger second half while demonstrating that its full-year performance is not excessively dependent on non-recurring licensing income.
Francis Van Parys is expected to provide a strategy update alongside the full interim results on August 19, 2026. Investors will look for greater clarity on cost discipline, regional strategy, clinical priorities and the route from adjusted EBITDA breakeven to positive cash flow.
Oxford Nanopore has already changed how and where sequencing can be performed. The unresolved question is financial. The company must prove that a globally distributed and continuously improving scientific platform can produce the margins, recurring revenue and operating discipline expected from a mature life-sciences technology business.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
